Breaking Finance News

Cantor Fitzgerald announced Abeona Therapeutics Inc (NDAQ:ABEO), raising its target price to $3.00 today

Only yesterday Abeona Therapeutics Inc (NDAQ:ABEO) traded -2.01% lower at $17.77. Abeona Therapeutics Inc’s 50-day moving average is $14.58 and its two hundred day average is $8.49. With the last stock price up 130.17% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time period. 3,006,952 shares of the stock were exchanged, up from an average trading volume of 976,925

Stating a potential downside of -0.83%, Cantor Fitzgerald bumped up the price target of Abeona Therapeutics Inc (NDAQ:ABEO) to $3.00

On 10/10/2017, Citigroup reported on Abeona Therapeutics Inc (NDAQ:ABEO) increased the target price from $0.00 to $32.00 that suggested an upside of 0.59%.

Performance Chart

Abeona Therapeutics Inc (NDAQ:ABEO)

Abeona Therapeutics Inc has 52 week low of $4.05 and a 52 week high of $22.75 and has a market cap of $0.

A total of 4 firms have released a research note on Abeona Therapeutics Inc. One broker rating the stock a strong buy, 3 brokers rating the stock a buy, zero brokerages rating the company a hold, zero firms rating the stock a underperform, and finally 0 firms rating the stock a sell with a one year target of $12.38.

More About Abeona Therapeutics Inc (NDAQ:ABEO)

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company's lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.